Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Interruptions to cancer treatment (chemotherapy delays/discontinuations) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (chemotherapy… compared with placebo; GRADE not reported.
1 finding from 1 review
Intervention not reported
Adverse events leading to treatment discontinuation ( · adults and adolescents with pleural TB
The intervention may leads to higher adverse events leading to treatment discontinuation ( (low certainty).
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether oxaliplatin changes treatment discontinuation due to toxicity compared with the same regimen including cisplatin (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in discontinuations due to adverse effects compared with doxycycline; GRADE not reported.
1 finding from 1 review
Discontinuation of medication due to adverse events · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher discontinuation of drug due to adverse effects compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Adverse effects: ocular allergy to the study medication requiring discontinuation up to 4 years' · people with open‐angle glaucoma
It is very uncertain whether neuroprotection changes adverse effects: ocular allergy to the study medication requiring… compared with control (very low certainty).
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
Deferasirox showed no clear difference in adherence: discontinuations compared with deferiprone (low certainty).
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
1 finding from 1 review
Adherence: Discontinuations · people with transfusion‐dependent thalassemia
1 finding from 1 review